$ATRS News

Last published 1y ago

1y agoATRSApproval of Xyosted (autoinjector), Nda #209863 (Labeling)FDA Approved DrugsApproval Date: 07/11/2025; Drug Name: Xyosted (autoinjector), Nda #209863; Active Ingredients: TESTOSTERONE ENANTHATE; Company: Antares Pharma Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 209863
3y agoSGTX VCEL OCAT ATRSDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorPR NewswireCHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board
4y agoATRS HALOHart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares PharmaPR NewswireSAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Halozyme's
4y agoATRS HALOHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAPR NewswireSAN DIEGO, April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstan
4y agoATRS CLVS GSK ONCY+2Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases IncreasingPR NewswirePALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab.
4y agoAAL ATRS CLSN CTIC+1Thinking about buying stock in Antares Pharma, Celsion Corp, American Airlines, Kaleido Biosciences, or CTI BioPharma?PR NewswireNEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRS, CLSN, AAL, KLDO, and CTIC.
4y agoATRS BLK BBBY JPM+7Stocks making the biggest moves premarket: Delta, JPMorgan, BlackRock and moreCNBCThese are the stocks posting the largest moves before the bell.
4y agoATRS HALOHalozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery LeaderPR NewswireTransaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad
4y agoATRSAntares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyGlobeNewswireEWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undeca
4y agoATRSAntares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsGlobeNewswireFull-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220
4y agoATRSAntares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceGlobeNewswireEWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and ho
4y agoATRSAntares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating ResultsGlobeNewswireEWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, Ma
4y agoATRSAntares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®GlobeNewswireEWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its New Drug Application ("NDA") resu
4y agoATRSAntares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis RescueGlobeNewswireEWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for ATRS-1902 f
4y agoATRSAntares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesGlobeNewswireEWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson w
4y agoATRSAntares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueGlobeNewswireEWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support
4y agoATRSAntares Pharma Announces Divestiture of Otrexup®GlobeNewswireEWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced the divestiture of OTREXUP® (methotrexate) injection for the treatment of rheumatoid arthritis to a
4y agoATRSAntares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewswireEWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and ho
5y agoATRSAntares Pharma to Present at the Jefferies London Healthcare ConferenceGlobeNewswireEWING, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and ho
5y agoATRSAntares Pharma Reports Third Quarter 2021 Financial and Operating ResultsGlobeNewswireIncreased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a speci
5y agoATRSAntares Pharma Announces Appointment of Carmen Volkart to its Board of DirectorsGlobeNewswireEWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member
5y agoATRSAntares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNAGlobeNewswireEWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that an abstract on XYOSTED®, a subcutaneous testosterone enanthate injection, was accepted as on or
5y agoATRSAntares Pharma to Report Third Quarter 2021 Financial and Operating ResultsGlobeNewswireEWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021,
5y agoATRSAntares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis RescueGlobeNewswireEWING, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that it has initiated a Phase 1 study for ATRS-1902 for adrenal crisis rescue. The development progr
5y agoATRSAntares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireEWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meet
5y agoATRSAntares Pharma Reports Second Quarter 2021 Financial and Operating ResultsGlobeNewswireIncreased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a spec
5y agoATRSAntares Pharma to Report Second Quarter 2021 Financial and Operating ResultsGlobeNewswireEWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021,
5y agoATRSAntares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis RescueGlobeNewswireEWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Applicatio
5y agoATRSAntares Pharma to Present at the Ladenburg Thalmann Annual Healthcare ConferenceGlobeNewswireEWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg
5y agoATRSAntares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial InfarctionGlobeNewswireEWING, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that its partner Idorsia Ltd ("Idorsia") initiated its Phase 3 registration study to evaluate the eff
5y agoATRSIdorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarctionGlobeNewswireAd hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3
5y agoATRSAntares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis RescueGlobeNewswireEWING, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Admin
5y agoATRSAntares Pharma to Present at the Raymond James Human Health Innovations ConferenceGlobeNewswireEWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond J
5y agoATRSAntares Pharma to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewswireEWING, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Jefferies
5y agoSYNH ATRSPhase 1 Study of ATRS-2002 in Healthy Male Adults - NCT04879589ClinicalTrials.govPharmacokinetic assessment, Pharmacodynamic assessment, Safety assessment, Local tolerability
5y agoATRSAntares Pharma Appoints Joseph Renda as Senior Vice President of CommercialGlobeNewswireEWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick
5y agoATRSAntares Pharma Reports First Quarter 2021 Financial and Operating ResultsGlobeNewswireIncreased Revenue 27% Year-Over-Year to $42.1 Million Increased Net Income to $3.8 Million, or $0.02 Per Basic and Diluted Earnings Per Share EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a spe
5y agoATRSAntares Pharma, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Antares Pharma, Inc. (NASDAQ:ATRS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 8:30 AM Eastern Time. To listen to the event live or access a r
5y agoATRSAntares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual MeetingGlobeNewswireEWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hyp
5y agoATRSAntares Pharma to Participate in the 7th Annual Truist Securities 2021 Life Sciences SummitGlobeNewswireEWING, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host in
5y agoATRSAntares Pharma to Report First Quarter 2021 Financial and Operating ResultsGlobeNewswireEWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, bef
5y agoATRSAntares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical OfficerGlobeNewswireEWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and
5y agoATRSAntares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating ResultsGlobeNewswireFull-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share Full-Year 2020 Net Income of $56.2 Million,...
5y agoATRSAntares Pharma to Present at Two Upcoming Investor ConferencesGlobeNewswireEWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
5y agoATRSAntares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating ResultsGlobeNewswireEWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and...
5y agoATRSAntares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare ConferenceGlobeNewswireEWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
5y agoATRSAntares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 MillionGlobeNewswireEWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects...
5y agoATRSAntares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewswireEWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
6y agoATRSAntares Pharma to Present at the Jefferies Virtual London Healthcare ConferenceGlobeNewswireEWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
6y agoATRSAntares Pharma Reports Strong Third Quarter 2020 Financial and Operating ResultsGlobeNewswireThird Quarter 2020 Revenue Increases 17% Year-Over-Year to $40.0 Million Third Quarter 2020 Net Income of $5.0 Million, or EPS of $0.03 EWING, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) --...